HBOT is not an established fertility treatment, and no randomized trials support it. The strongest evidence is a single 2025 pre-post cohort of 41 women with poor ovarian response, showing improved oocyte yield and embryo quality, plus a 2023 cohort in resistant thin-endometrium IVF patients. Anyone considering it should treat it as an unproven adjunct, coordinated with a reproductive endocrinologist, not as a standalone fertility solution.
How Might HBOT Affect Fertility?
Fertility depends on hormonal signaling, blood flow, tissue health, and cellular function. HBOT delivers 100% oxygen at raised pressure, sharply increasing dissolved oxygen in blood and tissue. Researchers have proposed several mechanisms through which that might influence reproduction, though all remain hypotheses.
Uterine Blood Flow and Endometrial Receptivity
Adequate blood supply to the uterus supports embryo implantation. HBOT stimulates angiogenesis and improves microcirculation in other clinical settings such as wound healing, so the theory is that better oxygen delivery to the endometrium could create a more favorable environment for implantation. Thin endometrium (below 7mm) is a recognized cause of implantation failure in IVF, and HBOT’s role in tissue repair and growth-factor release is why researchers have investigated whether it can improve endometrial thickness. The evidence remains observational, and HBOT is not FDA-approved for fertility.1
Ovarian Oxygenation and Oxidative Stress
Oxygen plays a role in follicular development and egg maturation, so some researchers hypothesize that increasing oxygen availability to ovarian tissue may support healthier egg development. Oxidative stress, an imbalance between free radicals and antioxidant defenses, is implicated in both male and female infertility. Although it seems counterintuitive that delivering more oxygen would reduce oxidative stress, HBOT can upregulate the body’s own antioxidant enzyme systems, which may offer a net protective effect on reproductive cells. This sits among the emerging uses covered in our guide to HBOT for chronic conditions, where observational data still outpaces randomized trials.
HBOT Fertility Evidence by Application
| Application | Best available evidence | Strength |
|---|---|---|
| Thin endometrium (IVF / FET) | Pre-post cohort (Chen 2023) | Emerging |
| Poor ovarian response | Pre-post cohort, n=41 (Meng 2025) | Emerging |
| Male sperm quality | Animal studies and case reports | Limited |
What Does the Research Say for Women?
The strongest signals come from two Chinese cohort studies, both without randomized controls. In a 2023 prospective pre-post cohort by Chen and colleagues, women with resistant thin endometrium (below 7mm despite standard and adjuvant therapies) received daily HBOT before frozen embryo transfer, and the study reported improved endometrial growth and pregnancy outcomes compared with a concurrent control group.1 A 2025 pre-post cohort by Meng and colleagues enrolled 41 women aged 20 to 45 with poor ovarian response and found HBOT significantly increased oocyte number, fertilization rate, and available embryos, with the benefit concentrated at 4 to 7 sessions.2
These are encouraging but preliminary. Both were small, neither was randomized or blinded, and neither has been replicated in large trials. Some clinics in Japan and Europe now offer HBOT as an IVF adjunct on this basis, but without randomized controls the effect of HBOT cannot be separated from other variables in a treatment cycle. For the wider evidence picture, see our HBOT research overview.
Does HBOT Improve Sperm Quality?
Male fertility data is even thinner, and most of it comes from animal studies and small case reports. Oxidative stress is a common identifiable factor in male infertility, contributing to sperm DNA fragmentation, poor motility, and abnormal morphology. Animal studies have shown HBOT can reduce oxidative markers in testicular tissue and improve sperm parameters in rodent models, and a handful of small, uncontrolled human case reports have described modest improvements in count or motility. None were blinded or controlled, and no conclusions can be drawn. HBOT for male fertility is a hypothesis supported by biological plausibility, not by clinical evidence.
What Do Fertility HBOT Protocols Look Like?
There is no standardized protocol. The parameters used in published studies and clinical practice vary, but some patterns recur. Learn more in our what to expect during treatment guide.
- Session count: Most protocols use 10 to 20 sessions; the 2025 poor-ovarian-response cohort found benefit concentrated at 4 to 7 sessions.
- Pressure: Usually 1.5 to 2.0 ATA, the lower to moderate end of clinical HBOT.
- Duration: 60 to 90 minutes per session.
- Frequency: Daily or near-daily over a 2 to 4 week period.
- Timing: For women in IVF, sessions are generally scheduled during the follicular phase or during endometrial preparation before a frozen embryo transfer.
These are based on small studies and clinical judgment, not dose-finding trials. Any fertility-related HBOT protocol should be coordinated between an HBOT provider and a reproductive endocrinologist. Our guide to HBOT sessions covers the practical side.
Is HBOT Worth Adding to IVF?
For most people, the honest answer is not yet. The evidence is very early: no large randomized trials exist, the positive studies are small and uncontrolled, and promising early results in reproductive medicine have often failed to hold up in rigorous trials. HBOT for fertility is not an FDA-approved indication, so no insurance covers it, and a 10 to 20 session course typically costs $2,000 to $6,000 or more on top of already expensive fertility treatment.
No credible provider offers HBOT as a replacement for conventional fertility care. If you have a specific issue such as resistant thin endometrium or repeated implantation failure, it may be reasonable to discuss a defined trial with your reproductive endocrinologist, who can weigh the cost and time against the thin evidence for your situation. Anyone marketing HBOT as a primary fertility solution should be viewed with skepticism.
Who Should Not Try HBOT
HBOT is generally safe under trained supervision, but not for everyone. The absolute contraindications are untreated pneumothorax (a collapsed lung, which pressure changes can make life-threatening) and certain drugs (bleomycin, cisplatin, doxorubicin, disulfiram). Relative contraindications, where a provider may modify or postpone treatment, include upper respiratory infection or sinus congestion, seizure disorder, COPD, high fever, prior ear surgery or chronic ear problems, claustrophobia, and pregnancy itself. Review the full HBOT side effects and risks and confirm timing with both your HBOT provider and your fertility doctor.
Frequently Asked Questions
Can hyperbaric oxygen therapy help me get pregnant?
There is no guarantee. Small cohort studies suggest HBOT may help in specific situations, particularly for women with resistant thin endometrium or poor ovarian response preparing for IVF. The evidence is preliminary, no randomized trials exist, and individual results vary. HBOT should be considered only as one part of a broader fertility plan, never as a standalone solution.
Is HBOT safe during pregnancy or while trying to conceive?
HBOT is generally considered safe when administered by trained professionals in a clinical setting. It is typically used before conception, for example during IVF preparation, rather than during pregnancy. The safety of HBOT during pregnancy has not been well studied for elective indications, so most providers limit its use to the pre-conception phase. Confirm timing with both your HBOT provider and your fertility doctor.
How many HBOT sessions are typically used for fertility support?
Most protocols described in the literature involve 10 to 20 sessions, usually daily or near-daily over 2 to 4 weeks before an IVF cycle or embryo transfer. The 2025 poor-ovarian-response cohort found the benefit concentrated at 4 to 7 sessions. There is no established standard, and your fertility specialist and HBOT provider should determine the plan together.
Sources
- Chen J, Huang F, Fu J, et al. Hyperbaric oxygen therapy: a possible choice for patients with resistant thin endometrium during frozen embryo transfer treatments. Reproductive Biology and Endocrinology. 2023;21(1):80. DOI: 10.1186/s12958-023-01123-4. PMID: 37658414.
- Meng W, Yang J, Lu Q, et al. Hyperbaric oxygen therapy improves oocyte yield and embryo quality in patients with poor ovarian response. Reproductive Biology and Endocrinology. 2025. DOI: 10.1186/s12958-025-01475-z. PMID: 41250167.
Medical Disclaimer
The content on BaricBoost.com is for informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
Author
Seph Fontane Pennock is the founder of BaricBoost.com and Regenerated.com, a clinic directory for regenerative medicine serving 10,000+ providers across the United States. He previously built and sold PositivePsychology.com, which grew to 19 million users and became the largest evidence-based positive psychology resource on the web. Seph brings direct experience as an HBOT patient, having completed protocols at clinics across three continents while navigating mold illness, systemic inflammation, and autoimmune conditions. His treatment journey includes hyperbaric oxygen therapy, peptide protocols, NAD+ therapy, and consultations with specialists from Dubai to Cape Town to Mexico. This combination of entrepreneurial track record and lived patient experience shapes everything published on BaricBoost.com. Every article is grounded in peer-reviewed research, informed by real clinical encounters, and written for patients making high-stakes treatment decisions. Seph's focus is on bringing transparency, scientific rigor, and practical guidance to the hyperbaric oxygen therapy space.
